JP2002153268A - Method for activating cell function and method for suppressing cell function and medicine and equipment used for the methods - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a method for activating cell functions and a method for suppressing cell functions, which enable the effective treatments of various diseases including fatal diseases and further enable the maintenance and promotion of health for disease prevention, aging prevention and the like, and to provide a medicine and equipment used for the methods. SOLUTION: This method for activating the cell functions comprises restoring and/or establishing micro-tubules 9 in a cell, activating motile protein 10 in the cell, or increasing the release of Ca2+ in the cell, thus enhances the concentration of Ca2+ at a local area in the cell. The method for suppressing the cell functions comprises inhibiting micro-tubules 9 in a cell inhibits motile protein 10 in the cell, or decreases the release of Ca2+ in the cell, thus lowers the concentration of Ca2+ at a local area in the cell.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a method for enhancing cell function and a method for suppressing cell function, which are useful for maintaining health and treating diseases. The present invention also relates to drugs and mechanical devices suitable for use in these.

[0002]

2. Description of the Related Art In a multicellular organism such as a human, a group of one or several types of cells forms a tissue, and some tissues form an organ having a certain structure or function. In addition, the collection of each organ forms each organ system, and each organ system constitutes an individual. Such diseases and disorders of multicellular organisms microscopically reflect cell-level disorders. Intractable diseases such as cancer, AIDS, and dementia are no exception, because abnormalities, defects, destruction, and disappearance of cells are caused by endogenous and exogenous factors.

[0003] In terms of cells, the same actin fibers as muscle contraction components exist in general cells. It is called non-muscle actin. Non-muscle actin has long been known to be responsible for cell division, phagocytosis of leukocytes, etc., plasma flow, gastrulation, and various other basic life phenomena. However, the detailed mechanism has not been elucidated. Furthermore, it is not known that individual cells change shape (have polarity) to perform their functions, actin fibers are unevenly distributed, and that cell movement occurs at that site. However, the mechanism of intracellular localization (localization) of actin fibers was completely unknown.

[0004] Non-muscle actin reacts with myosin like muscle actin, and contracts by Ca ²⁺ using the energy of adenosine triphosphate (ATP). Intracellular Ca
²⁺ is always kept at a low concentration by the action of two kinds of Ca ²⁺ pumps. One of the pumps is
Pumping ²⁺ out of the cell, another one of the pumps, is to pump Ca2 ⁺ into the Ca2 ⁺ store on the membrane of the intracellular Ca2 ⁺ store (Ca2 ⁺ store). When cells become deformed or activated, Ca ²⁺ concentrations also temporarily increase locally within the cells. The reason is that Ca ²⁺ influx from Ca ²⁺ channels on the cell membrane and Ca ²⁺ on Ca ²⁺ reservoirs
^This is because Ca ²⁺ efflux from the ²⁺ channel causes a transient increase in Ca ²⁺ in the cell. In this regard, the IP ₃ (inositol triphosphate) receptor of the Ca ²⁺ channel on the membrane of the Ca ²⁺ reservoir is of particular importance. That is phospholipid degradation of cell membranes by stimulation from the extracellular, when the IP ₃ caused thereby bound to the IP ₃ receptor, than Ca ²⁺ to flow out IP ₃ receptor is opened. This is what is referred to as IP ₃ induces ^{Ca 2+} release.

[0005] On the other hand, it is well known that the elucidation at the cell level and the gene level is proceeding at a higher speed than expected for countermeasures against intractable diseases such as cancer, AIDS and dementia.
Based on this knowledge, physical therapy, chemotherapy, immunotherapy,
Gene therapies are being developed one after another and they are contributing in the medical field. Nevertheless, there are no established therapeutic agents or techniques to cure (completely cure) this kind of intractable disease.

[0006]

The matters known about the intracellular phenomenon are as described above. At present, there are no new research reports that exceed it. Of course, there is no research report that elucidated the uneven distribution of actin in cells in relation to diseases and diseases. If the body recovers its function,
If the mechanism of actin uneven distribution can be elucidated in relation to the prevention of aging, etc., and if the technology based on it can help maintain, promote and recover health, it will greatly contribute not only to daily life but also to the medical field. There is an urgent need to establish such treatment techniques, especially for intractable diseases for which there is no effective treatment.

[0007]

SUMMARY OF THE INVENTION The present invention has been made in view of such technical problems.
It provides a method for cell function enhancement and cell function suppression that can effectively treat various diseases and disorders including intractable diseases, and is also effective for maintaining and promoting health with the aim of preventing diseases and preventing aging. In addition, it is intended to provide a drug or a mechanical device used for these.

[0008]

The method for enhancing cell function according to claim 1 of the present invention is characterized by the following means for achieving the intended purpose. That is, in the method for enhancing cell function according to the first aspect, in the cell, the microtubule extends toward the local area, and the Ca ²⁺ storage moves along the microtubule with the motility protein (motor protein) and accumulates in the local area. and, in order to increase the range of cellular functions that at the local is IP ₃ induces Ca ²⁺ release there Ca ²⁺ concentration caused increases, to repair and / or new microtubules within the cell, motility intracellular Activating proteins,
Enhancing intracellular Ca ²⁺ release, including one or more of these, thereby increasing local Ca ²⁺ concentration within the cell.

According to a second aspect of the present invention, there is provided the method for enhancing cell function according to the first aspect, wherein a physical stimulus is applied to the cell, a chemical stimulus is applied to the cell, and a tubulin gene is introduced. , introducing the gene of the microtubule-associated protein, introducing a movement protein gene, to increase the IP ₃ production in cells, IP ₃
Increasing the activity of the receptor, including one or more of these.

[0010] A mechanical device according to a third aspect of the present invention is characterized by the following means for solving the problem in order to achieve the intended object. That is, a mechanical device according to a third aspect is for applying a physical stimulus to a cell, and is characterized by comprising an alternating magnetic field generating means.

[0011] The drug according to claim 4 of the present invention is characterized by the following means for achieving the intended purpose. That is, the drug according to claim 4 is for increasing intracellular Ca ²⁺ release, and is characterized by being composed of a substance that gives energy to a motile protein and activates it.

The medicine according to claim 5 of the present invention is characterized by the following means for solving the problem in order to achieve the intended purpose. That is, the drug according to claim 5 is for increasing intracellular Ca ²⁺ release, and is characterized by comprising a substance that promotes the production of IP ₃ .

[0013] A method for suppressing cell function according to claim 6 of the present invention.
Has identified the following solutions to achieve the intended purpose.
Sign. That is, the cell function suppressing method according to claim 6.
Means that in the cell, microtubules extend to the local
Ca within²⁺Reservoir is more sensitive to motile proteins
It moves along the tubule and accumulates in the above-mentioned area, where I
P₃Induced Ca²⁺Release occurs and Ca there²⁺Concentration above
In order to suppress a series of cellular functions of
Inhibits microtubules, inhibits motility proteins in cells
Harm, intracellular Ca²⁺Reduce emissions
And one or more of these,
Is the intracellular local Ca ²⁺The feature is to decrease the concentration.
Sign.

According to a seventh aspect of the present invention, there is provided the method for suppressing cell function according to the sixth aspect, in which a cell is physically damaged, a cell is chemically damaged, and a mutant tubulin gene is introduced. it, introducing the microtubule-associated protein variant gene, introducing the motility protein variant genes, to inhibit IP ₃ production in cells, inhibiting the function of IP ₃ receptor, any of these Or one or more.

The drug according to claim 8 of the present invention is characterized by the following means for achieving the intended purpose. That is, the drug according to claim 8 is for reducing intracellular Ca ²⁺ release, and is characterized by comprising a substance that inhibits microtubules.

The drug according to claim 9 of the present invention is characterized by the following means for achieving the intended purpose. That is, the drug according to claim 9 is for reducing intracellular Ca ²⁺ release, and is characterized by being composed of a substance that inhibits a motility protein.

The medicine according to claim 10 of the present invention is characterized by the following means for achieving the intended purpose.
That is, the drug according to claim 10 is characterized in that intracellular Ca ²⁺
Been made in an effort to reduce the emission, characterized in that a substance which inhibits the production of IP _3.

The medicine according to claim 11 of the present invention is characterized by the following means for achieving the intended purpose.
That is, the drug according to claim 11 is characterized in that intracellular Ca ²⁺
It has been made in an effort to reduce the emission, characterized in that a substance that inhibits IP ₃ receptor.

[0019]

[Action] New findings obtained from research and experiments on the present invention
Is as follows: Ca²⁺The storehouse
Along the microtubules that serve as
(Localized protein) and accumulated locally within the cell (partial
). Accumulated Ca²⁺Storage (Ca²⁺Store)
IP₃Due to the presence of the receptor, IP₃
Or rises, then IP₃Induced Ca²⁺Release
Local Ca in the cell²⁺The concentration increases. this is
Microtubules, motile proteins, IP₃Any one of
By manipulating one or more artificially, local Ca
²⁺That the density can be controlled dynamically.
To taste. Furthermore, movement and activation are localized within cells.
When it arises, first the rail bar around that part
Microtubules are laid, and then motile proteins are activated.
And then IP₃Ca with receptor²⁺Storage is fine
Localized by tubule guidance and the energy of motile proteins
I do. This Ca²⁺The reservoir is bound to actin
And actin and actin-binding proteins also accumulate there.
You. In such an integrated state, IP₃Rise → IP₃
Induced Ca²⁺Release → local Ca²⁺A series of phenomena such as rising
And the movement of the actin-myosin system based on it
Actin and myosin contract, resulting in cell movement and activity
Transformation occurs. As is clear from this description, the IP₃Acceptance
Ca with body²⁺The reservoir binds to non-muscle actin and
Become a carrier of Kuching fibers. This is the action within the cell.
This is the mechanism of uneven distribution (localization) of chin fibers.

It has already been mentioned that non-muscle actin is known as a life phenomenon in which cell division, phagocytosis of leukocytes, etc., cytoplasmic flow, gastrulation, etc. are known. In addition, recently, various life phenomena such as memory phenomenon of the nervous system, extension of nerve cell processes, migration and metastasis and invasion of cancer cells, activation of lymphocytes responsible for immunity, endocytosis (uptake), The movement and uneven distribution of non-muscle actin is considered to be the main mechanism. Therefore, the mechanism elucidated above becomes a common principle also in these important life phenomena.

The present invention, based on the fact that the common principle of life phenomena has been clarified as described above, has established a technique for treating or ameliorating plagues and pathological diseases involving those life phenomena. is there. It is provided in the form of a method for enhancing cell function and a method for suppressing cell function, as well as drugs and mechanical devices used in these methods. This is roughly described below with reference to a newly elucidated mechanism.

[0022] Some of the declines in body functions, ordinary diseases, illnesses, and incurable diseases occur because the Ca ²⁺ concentration does not increase locally in cells. For these, the Ca ²⁺ concentration may be increased locally. One of them is to repair and / or rebuild microtubules in cells,
The other is to activate intracellular motility proteins, and the other is to increase intracellular Ca ²⁺ release. Of course, two or more of these may be performed. When the cell function is enhanced in this way, the body function is restored or improved normally, and various illnesses including intractable diseases are shown to have an effect of improvement or cure. In specific cases, for example, patients with dementia caused by neuronal dysfunction, such as patients with early Alzheimer's disease, are given gene therapy to create new normal microtubules (rails), Activating motor proteins during treatment. Immunodeficiency in which lymphocyte activation does not occur normally ・ Immune deficiency due to inadequate phagocytosis of leukocytes and macrophages ・ AIDS ・ Insufficiency in neurogenesis ・ Insufficiency in nerve cell regeneration and synapse formation ・ Cells Increasing the local Ca ²⁺ concentration is also an effective treatment for abnormal division and insufficient cell migration. On the other hand, it may be better to suppress cell function for certain diseases. Diseases whose cell function should be suppressed are, for example, tumor cells in which the cells proliferate autonomously due to irreversible changes. Over time, it changes into an undifferentiated cell, causing rapid growth and infiltration and metastasis to the surroundings.
Cancer (malignant tumor) that eventually kills the host
This is a typical example of such an intractable disease. Contrary to the above, they inhibit intracellular microtubules, inhibit intracellular motility proteins, and further inhibit intracellular Ca ²⁺
Decrease release or reduce local Ca ²⁺ concentration in cells. By doing so, cancer cells and the like are inhibited from undergoing cell division and cell migration, so that carcinogenicity is suppressed or inactivated. In a disease caused mainly by neuronal death such as Alzheimer's disease at a later stage, continuous intracellular Ca ²⁺ release from intracellular Ca ²⁺ reservoir causes intracellular calcium to rise and neurons to die. For such cases a patient, administered IP ₃ receptor inhibitors, commonly sponge called IP ₃ absorbers such as an IP ₃ production inhibitor heparin as lithium, intracellular Inhibits cell function by inhibiting Ca ²⁺ release. Thus, neuronal cell death can be prevented beforehand or its progress can be stopped, so that dementia, which tends to become serious, can be significantly treated.

[0023]

BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of a method for enhancing cell function and a method for suppressing cell function according to the present invention, and a drug and a mechanical instrument used in these methods will be described below.

FIG. 1 schematically shows cells of a multicellular organism such as a human.
ing. In FIG. 1, Ca is deposited on the cell membrane 1.²⁺pump
2 and Ca²⁺There is channel 3 and nucleus 4
Cytoplasm 5 ・ Ca²⁺There are storage 6 and others. In cytoplasm 5
Ca²⁺Is usually kept low as described above.
You. Ca²⁺Ca is also present on the membrane of the storage 6. ²⁺Pump 7 or C
a²⁺There is channel 8. Ca²⁺Ca in the storage 6
²⁺Is more than that of cytoplasm 5.

FIG. 2 schematically shows the activity of the cells. In FIG. 2, an external stimulus (chemical stimulus and / or physical stimulus) is applied to the local area 0 of the cell. The cell stimulated at the local area 0 changes its shape while distributing the nucleus 4 to the opposite side of the stimulus. Ca Within this cell, together with microtubules 9 elongation or motile proteins 10 over the local 0 or activated from the vicinity of the nucleus 4, carrying an IP ₃ receptor
²⁺ storage 6 guides microtubules 9 and motile proteins 10
Or with local energy. Since the Ca ²⁺ storage 6 is bound to the actin fiber 11, actin and actin-binding proteins also accumulate there. This increases IP ₃ → IP ₃ induced Ca ²⁺ release → local 0 Ca
²⁺ rise and the like, and the actin-myosin system contractile movement occurs, so that the cells are activated and activated. When cells function normally, they are healthy. Conversely, in the case of poor health or a diseased body, cells do not function normally because of impairment of microtubules, motility protein, Ca ²⁺ release, and the like.

When treating a person with impaired cell function, reinforcing intracellular microtubules 9, activating intracellular motility protein 10, intracellular Ca ²⁺
Increased release, any one or more of these treatments may be applied to enhance the function of the cells, thereby increasing the local Ca ⁰⁺ concentration in the cells. Specifically, applying physical stimulation to cells, applying chemical stimulation to cells, introducing a tubulin gene, introducing a gene for a microtubule-related protein, introducing a gene for a motility protein. , Intracellular IP ₃
Increasing production, increasing the function of IP ₃ receptor, it may be subjected to any one or more treatments selected from among these.

When a human cell is given a physical stimulus to increase the intracellular Ca ²⁺ concentration, for example, a site exhibiting symptoms, a site related thereto, a whole body, or the like may be used.
Irradiate with 0-60 Hz alternating current magnetism (0.05-0.1 Tesla). In this case, the irradiation time per one time is 20-6.
At 0 minutes, this is carried out in the range of 1 to 10 times per day, preferably in the range of 3 to 7 times per day. When a human cell is subjected to chemical stimulation to increase the intracellular Ca ²⁺ concentration, a drug for the drug is injected into the affected area, or the drug is taken internally. The procedure for introducing the tubulin gene is as follows. First, DNA is taken out from a DNA donor cell, and a necessary portion is cut out with a restriction enzyme. Next, the plasmid is extracted from the recipient cells. Thereafter, a part of the DNA of this plasmid was cut out with a restriction enzyme, and the DNA of the donor prepared above was replaced with D
Attach the missing part of the plasmid with NA ligase. In the following, the recombinant plasmid (recombinant molecule) is returned to the recipient cells, and tubulin is propagated. The same applies when a gene for a microtubule-related protein is introduced. When the motility protein gene is introduced, the motility protein may be propagated in the cells by a method similar to the tubulin gene introduction method. Adenosine triphosphate (ATP) may be increased to obtain high energy of motility proteins. When increasing the function of and IP ₃ receptor when increasing the IP ₃ production in cells, using the activator suitable for them.

When inhibiting the function of a cell, for example, inhibiting the function of a cancer cell in a cancer condition, inhibiting the intracellular microtubule 9, inhibiting the intracellular motility protein 10, Intracellular Ca ²⁺ release may be reduced, and any one or more of these treatments may be administered to suppress cell function, thereby lowering local Ca ²⁺ concentration in the cell. Specifically, causing physical damage to cells, causing chemical damage to cells, introducing a mutant tubulin gene, introducing a microtubule-related protein mutant gene, introducing a motility protein mutant gene to it, to inhibit IP ₃ production in cells, inhibiting the function of IP ₃ receptor, it may be subjected to any one or more treatments selected from among these.

When a human cell is physically impaired to lower the Ca ²⁺ concentration in the cell, for example, a target site (carcinogenic site) may be targeted and an alternating magnetic field (high energy)
Irradiation with a heavy particle beam, radiation, ultrasonic waves, or the like may be performed. When a human cell is subjected to chemical stimulation to increase the intracellular Ca ²⁺ concentration, a drug for it is injected into the affected area, or
Or take medicine for it. The procedure for introducing a mutant tubulin gene is as follows. Introduction DNA
The DNA is removed from the donor cells, and the necessary portions are cut out with restriction enzymes. Next, the plasmid is extracted from the recipient cells. Thereafter, a part of the DNA of this plasmid was cut out with a restriction enzyme, and the DNA of the donor prepared above was prepared.
To the missing portion of the plasmid with DNA ligase. The following is the plasmid after completion of recombination (recombinant molecule)
To the recipient cells to inhibit tubulin. When introducing a microtubule-related protein mutant gene or a motility protein mutant gene, the target may be inhibited in cells by a method similar to the method for introducing a mutant tubulin gene. Adenosine triphosphate (AT
Inhibitors of P) may reduce or eliminate the high energy of motile proteins. When you suppress the function of IP ₃ receptor or reduces the IP ₃ production in cells, using Toka inhibitor Toka inhibitors suitable for them.

The instrument of the present invention used to carry out the method of the present invention will be described with reference to FIG.

In the machine illustrated in FIG. 3, a coil 21 for generating an alternating (alternating) magnetic field is housed and held in a case 22 made of a non-magnetic material, for example, a synthetic resin. Is attached to the mounting tool 24. The case 22 has an AC magnetism generating surface 23 having the strongest magnetic force, and the surface 23 is exposed on the inner surface of the mounting tool 24. On the other hand, an outlet 25 for supplying an alternating current is connected to the coil 21 by a wire cord 26.

The mechanical device shown in FIG. 3 is used, for example, in the above-mentioned case in which a physical stimulus is applied to a cell to increase the Ca ²⁺ concentration in the cell. In such a case, the coil 21 is energized after the belt-shaped wearing device 24 is wound around a predetermined part of the body and the AC magnetic generating surface 23 is applied to the affected part. Thus, the cells in the affected area receive the alternating current magnetism (0.05 to 0.1 Tesla) from the coil 21. As already mentioned in the received AC magnetic cell, IP ₃ increases → IP ₃ induces Ca
²⁺ release → local 0 Ca ²⁺ rise, etc., and contraction movement of the actin-myosin system occurs, so that the cells are activated and activated. By doing so, it is possible to treat various diseases and disorders resulting from the decrease in cell function.

With respect to the above-mentioned mechanical devices, there are also the following embodiments. One of them is to provide a plurality of coils 21 in a case 22. The other one is coil 2
That is, a plurality of the two cases 22 are attached to the mounting tool 24. Still another is to make the wearing tool 24 into a cap shape (hat shape) corresponding to a human head. The other one is to change the attachment 24 to a mattress,
That is, the coil 22 covered with the case 22 or the cover is attached to the mattress in a dotted manner. With this mattress structure, the whole body can be irradiated with AC magnetism.

One of the agents according to the present invention is the intracellular Ca
^It is intended to increase ²⁺ release and is used as a means of the above treatment. The drug Concrete examples of substances that promote the production of substances and IP ₃ to activate it by applying energy to the movement protein and the like. For the former there is adenosine triphosphate (ATP) and for the latter there is adenophosphin. As an agent for increasing intracellular Ca ²⁺ release, in addition to those listed here, agents exhibiting the same medicinal effects can also be used. These drugs may be used alone or in combination of two or more.

Another one of the agents according to the present invention is the intracellular C
It is for ^reducing a ²⁺ release and is used as one means of the above treatment. Say this specifically, a substance that inhibits the substance or motility proteins that inhibit microtubule and materials can be mentioned for further inhibits the production of IP _3. These substances may be toxin-based or poison-based. Examples of microtubule inhibitors include colchicine, taxol and vinblastine. Motility protein inhibitors include ATP inhibitors. Further I
The inhibitor of P ₃ -IP ₃ receptor system, be given IP ₃ receptor inhibitors, IP ₃ production inhibitor-profane IP ₃ absorber is referred to as the sponge, such as lithium, such as Peparin it can. Also for the purpose of ^reducing intracellular Ca ²⁺ release, in addition to those listed here, agents exhibiting the same medicinal effects can be used. These drugs may also be used alone or in combination.

Although the method, drug, and mechanical device of the present invention have been mainly described above with reference to the case of humans, multicellular organisms other than humans (especially animals and plants) can also be used.
These can be applied.

[0037]

DESCRIPTION OF THE PREFERRED EMBODIMENTS One embodiment of the present invention will be described below based on a specific example.

The patient is a 54 year old female who has developed a memory impairment. The patient was diagnosed with Alzheimer's dementia at a university hospital. For treatment, the patient was administered an anticholinesterase drug.
He began to repeat the same thing "several tens of times a day" from about a month, and could not do any housework around three months after the onset. The patient was treated as described below.

Initially, alternating current magnetic therapy was applied to a patient using the mechanical device of the present invention. Specifically, four machines and instruments of the present invention (a total of 12 machines) were applied to the head and 8 machines were applied to the whole body, and were irradiated with 800 gauss of alternating magnetic field for 30 minutes per time and 6 times a day. After the start of this treatment, the patient's memory disorder gradually improved, and after 5 months from the onset, he did not repeat the same thing, and was able to do housework such as cooking and washing. This condition lasts up to 12 months after onset. However, from the 13th month after the onset, the aforementioned memory disorder, repetitive remarks of the same thing, and inability to do housework appeared again.

As the next treatment, lithium carbonate (6 times daily)
00 mg) was administered to the patient. About 2 weeks after the administration, the memory disorder improved, and after about 3 weeks from the administration, the same thing was not repeated and housework was possible again. This condition continues even now, one year and six months after the onset.

As described above, it is effective to administer alternating current magnetic therapy or administer lithium according to the degree of the symptom, for a disease or disease caused by a decrease in the function of nerve cells or death of nerve cells.

[0042]

As described above, the method, drug and mechanical device of the present invention enhance the cell function by increasing the intracellular local Ca ²⁺ concentration, or enhance the intracellular local Ca ^2+. The cell function is suppressed by lowering the concentration. Among them, when the cell function is enhanced, not only normal diseases and diseases but also AID
S can also improve or treat various intractable diseases including neuronal functional abnormalities in dementia, and when cell function is suppressed, cancer or nerve cell death in dementia can be reduced. Can be improved or treated. Therefore, the method / medicine / mechanical device of the present invention can be expected to have an epoch-making therapeutic effect in the medical field, and greatly contributes to these.

[Brief description of the drawings]

FIG. 1 is a diagram schematically illustrating cells of a multicellular organism.

FIG. 2 is a diagram schematically showing how a cell moves.

FIG. 3 is a perspective view showing an embodiment of the mechanical device according to the present invention.

[Explanation of symbols]

0 Localization of Cell 1 Cell Membrane 2 Ca ²⁺ Pump 3 Ca ²⁺ Channel 4 Cell Nucleus 5 Cytoplasm 6 Ca ²⁺ Storage 7 Ca ²⁺ Pump 8 Ca ²⁺ Channel 9 Microtubule 10 Motility Protein 10 11 Actin Fiber 21 Coil 23 AC Magnetic Generating Surface

Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat II (reference) A61P 35/00 A61P 43/00 107 4C086 43/00 105 C12M 1/42 4C106 107 C12N 13/00 C12M 1/42 A61K 33 / 00 C12N 5/10 C12N 5/00 E 13/00 A61N 1/42 Z 15/09 C12N 5/00 B // A61K 33/00 15/00 A F term (reference) 4B024 AA01 BA80 CA01 DA03 EA04 GA11 4B029 AA27 BB11 4B033 NG05 NH04 NJ02 NK01 4B065 AA93X AA93Y AB01 BA01 CA24 CA44 4C084 AA17 MA01 NA14 ZA152 ZB212 ZB222 ZB262 ZB332 4C086 AA01 HA02 HA16 NA14 ZA15 ZB21 ZB22 ZB26 ZB33 CCB CC4CC

Claims (11)

[Claims] 1. A intracellularly, elongation microtubules toward the local, Ca ²⁺ reservoir moves along microtubules integrated to the local by motility protein, IP ₃ induced Ca ²⁺ release in the local is Repairing and / or renewing microtubules in cells, activating motility proteins in cells, increasing Ca in cells to enhance a series of cellular functions that occur and increase the concentration of Ca ²⁺ there. ^{Increasing 2+} release, including any one or more of these,
A method for enhancing cell function, which comprises increasing local Ca ²⁺ concentration in a cell. 2. applying a physical stimulus to the cell, applying a chemical stimulus to the cell, introducing a tubulin gene, introducing a gene for a microtubule-related protein,
Introduction of motility protein gene, intracellular IP
Increasing the ₃ production, IP ₃ to increase the action of receptors, cell hyperactivity method of claim 1, including any one or more of these. 3. A mechanical device for applying a physical stimulus to a cell, comprising a means for generating an alternating magnetic field. 4. An agent for increasing intracellular Ca ²⁺ release, comprising a substance that gives energy to a motile protein and activates it. 5. Medicaments been made in an effort to increase the Ca ²⁺ release intracellular made of a substance that promotes the production of IP _3. 6. The intracellular growth microtubules toward the local, Ca ²⁺ reservoir moves along microtubules integrated to the local by motility protein, IP ₃ induced Ca ²⁺ release in the local is Inhibits microtubules in cells, inhibits motility proteins in cells, and reduces intracellular Ca ²⁺ release to suppress a series of cellular functions that occur and increase the Ca ²⁺ concentration there. A method for suppressing cell function, comprising: reducing one or more of these intracellular Ca ²⁺ concentrations. 7. Inducing physical damage to cells, causing chemical damage to cells, introducing a mutant tubulin gene, introducing a microtubule-associated protein mutant gene, introducing a motility protein mutant gene. to it, to inhibit IP ₃ production in cells, inhibiting the function of IP ₃ receptor, the method of cell function suppressing claim 6 comprising either one or more of these. 8. An agent for ^reducing intracellular Ca ²⁺ release, which comprises a substance that inhibits microtubules. 9. A drug for ^reducing intracellular Ca ²⁺ release, which comprises a substance that inhibits a motility protein. 10. Intracellular Ca²⁺To reduce emissions
IP ₃Consisting of substances that inhibit the production of
Agent. 11. Intracellular Ca²⁺To reduce emissions
IP ₃Drugs consisting of substances that inhibit receptors
Agent.